Innovative Strength Recognized Again! Genuine Biotech Wins "Excellent Biopharmaceutical Company of the Year" Award

Recently, the "Technology Empowers, Capital Breaks Through" sharing meeting sponsored by GuruClub was successfully held, during which the "Jinge Award" - the list of excellent companies of the year was officially unveiled, and Genuine Biotech won the "Excellent Biopharmaceutical Company of the Year" Award by virtue of its outstanding performance and professional strength in the biopharmaceutical field.

The assessment covered all listed companies on the Hong Kong Stock Exchange, Shanghai Stock Exchange and Shenzhen Stock Exchange, and unicorn enterprises, aiming to create an industry evaluation system with important reference value for the investment circle.Looking back to 2025, Genuine Biotech has made a series of important advances in the field of innovative drug research and development, and several pipelines have seen key breakthroughs, reflecting the Company's expertise and unique value in the field of major disease treatment.

In the antitumor field, Dosimertinib, a third-generation EGFR-TKI developed independently by the Company, has made significant progress: the phase II clinical trial protocol has been approved by the Center for Drug Evaluation of the National Medical Products Administration, and the first patient was enrolled in June.Results from preclinical trials have shown that, compared with Osimertinib, Dosimertinib reduced potential toxic metabolites by up to 80%, and exhibited higher levels of the unchanged drug in lung and brain tissues, which makes Dosimertinib advantageous for the treatment of lung cancer and brain metastases from lung cancer.

Data from the phase I trial further verified the favorable safety and dose-related effects, with all 3 patients in the 240 mg dose group showing significant results: 1 patient had stable disease (SD) with disappearance of non-target lesions in the brain; 2 patients achieved partial response (PR), with disappearance of the non-target lesions (left upper lobe, left lower lobe, and left pleura) in one of the patients.

Its combination therapy development has also made milestone progress. In September, Azvudine and Dosimertinib combination therapy for the treatment of non-small cell lung cancer was approved for clinical trials. In the combination therapy, Dosimertinib blocks the epidermal growth factor receptor (EGFR) signaling pathway by targeting EGFR, thus inhibiting the proliferation and metastasis of tumor cells; Azvudine enhances the function of immune cells by inhibiting the DNA synthesis of the tumor cells in a highly selective manner, thus improving the overall antitumor efficacy. The combination antitumor study has shown a tumor inhibition rate of up to 92.82% in the animal model.

In addition, Azvudine has also made new progress in the field of hematological oncology treatment, receiving approval for a phase IIa clinical trial for the treatment of malignant hematological tumors in December, which will further evaluate the safety and preliminary efficacy of Azvudine in patients with malignant hematological tumors based on previous studies.

In the antiviral field, Genuine Biotech's pipelines are likewise advancing steadily. The phase IIa clinical trial of the novel long-acting HIV drug candidate CL-197 has been formally initiated. A study in animal model has shown that its half-life in PBMCs was approximately 168 hours following oral gavage. The results from the phase I clinical trial were also encouraging, with favorable performance in safety, tolerability, and pharmacokinetics.

In addition, Genuine Biotech also plans to develop an all-oral, long-acting combination tablet based on the potential long-acting effect of Azvudine combined with CL-197 in the treatment of HIV infection, which is expected to be the world's first all-oral, long-acting, once weekly HIV drug.

The "Excellent Biopharmaceutical Company of the Year" is a high recognition of Genuine Biotech's professional strength in the field of innovative drug research and development. By building product pipelines with synergistic effects, the Company has developed unique competitive advantages in antiviral and antitumor fields.

In the future, Genuine Biotech will continue focusing on major disease fields, accelerate the clinical progress of the pipeline, and provide patients with more effective treatment options through continuous innovation.

* The relevant pipeline content in this article is a sharing of information on scientific progress and does not constitute any medical advice. Specific disease diagnosis and treatment regimens need to be determined by a licensed physician after a thorough evaluation.